Boston Scientific Corp
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Boston Scientific Corp (BSX). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Cardiovascular | $3.09B 66.2% | $3.35B 66.1% | $3.50B 67.3% | $3.62B 66.6% |
| MedSurg | $1.58B 33.8% | $1.72B 33.9% | $1.70B 32.7% | $1.82B 33.4% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by region
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| U.S. | $2.96B 63.5% | $3.22B 63.7% | $3.28B 63.1% | $3.43B 62.9% |
| Int'l | $1.70B 36.5% | $1.84B 36.3% | $1.92B 36.9% | $2.02B 37.1% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.12B 24.1% | $1.18B 23.3% | $1.24B 23.9% | $1.33B 24.5% |
| Electrophysiology | $730.0M 15.7% | $840.0M 16.6% | $905.0M 17.4% | $916.0M 16.8% |
| Endoscopy | $673.0M 14.4% | $737.0M 14.6% | $736.0M 14.2% | $793.0M 14.6% |
| Urology | $633.0M 13.6% | $676.0M 13.4% | $646.0M 12.4% | $684.0M 12.6% |
| Cardiac Rhythm Management | $578.0M 12.4% | $590.0M 11.7% | $578.0M 11.1% | $585.0M 10.7% |
| Watchman | $425.0M 9.1% | $486.0M 9.6% | $506.0M 9.7% | $507.0M 9.3% |
| Neuromodulation | $271.0M 5.8% | $303.0M 6.0% | $318.0M 6.1% | $341.0M 6.3% |
| Interventional Oncology & Embolization | $228.0M 4.9% | $251.0M 5.0% | $268.0M 5.2% | $283.0M 5.2% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.